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AbstrACt
Objectives We evaluated 300 paediatric trials to 
determine: the consent and recruitment strategies used, 
who trial information was targeted to, how incentives were 
used and if they achieved their recruitment targets.
Methods For this cross-sectional evaluation, we 
searched the Cochrane Central Register of Controlled 
Trials for paediatric trials published in 2012 and randomly 
selected 300 that reported on outcomes for participants 
aged ≤21 years. We collected data on consent and 
recruitment procedures for each trial and undertook 
descriptive analyses in SPSS statistics V.23.
results All but one trial (99.7%) used a standard 
recruitment strategy. Most (92%) trials reported that 
consent was obtained but only 13% reported who obtained 
consent. Two-thirds (65%) of trials included school-
aged participants, and of these 68% reported obtaining 
assent. Half (50%) of the trials reported who the trial 
information was targeted to. Most trials (75%) of school-
aged participants targeted information towards children 
or children and their parents. Fourteen per cent of trials 
reported using incentives, half (50%) of which were in 
the form of compensation. Only 48% of trials reported 
sufficient data to determine if their recruitment targets 
were achieved. Of these, 70% achieved their targets.
Conclusions Notable reporting shortcomings included: 
how families were recruited into the trial, who obtained 
consent and/or assent and how, who trial information was 
directed to, whether incentives were used and sufficient 
data to determine if the recruitment target was achieved. 
Forthcoming paediatric-specific reporting standards may 
improve reporting in this priority area. Our data provide 
a baseline for ongoing monitoring of the state of the 
research.
IntrOduCtIOn
In 2012, Standards for Research in (StaR) 
Child Health published six evidence-based 
standards to guide the rigorous design, 
conduct and reporting of paediatric 
trials.1 2 Each standard3–8 includes practice 
recommendations and a research agenda to 
address knowledge gaps. To characterise the 
state of the literature, we analysed a random 
sample of 300 paediatric trials published in 
20129 and identified various shortcomings in 
their conduct and reporting. Among other 
issues, most trials reported results that were 
at unclear or high risk of bias, and only 46% 
were registered in a clinical trial registry.9 
Trialists are ethically obligated to opti-
mise the value of children’s participation 
in research by safeguarding them from 
avoidable harms,10 11 using rigorous meth-
odologies12 and reporting their findings 
transparently.13 Ethically sound recruitment 
and consent procedures include: obtaining 
consent from parents and assent from chil-
dren, approaching all eligible children 
and not unfairly excluding any children, 
providing families with age-appropriate trial 
information, ensuring that incentives do not 
influence children’s decision-making and 
clearly differentiating between elements of 
standard care and those that are part of the 
trial.3 Safeguarding children from avoidable 
harm also includes carefully planned recruit-
ment targets. Trials that recruit too many 
participants needlessly expose children to 
the burdens of research participation, while 
What is already known on this topic?
 ► In 2012, Standards for Research in Child Health pub-
lished evidence-based guidance to inform ethical-
ly sound recruitment and consent in paediatric trials, 
and identified knowledge gaps.
 ► To optimise the value of children’s participation in 
research, trialists must safeguard them from avoid-
able harm, use rigorous methodologies and report 
their findings transparently.
What this study hopes to add?
 ► Reporting shortcomings included: how families were 
recruited, who obtained consent/assent, who trial in-
formation was directed to, whether incentives were 
used, if recruitment targets were reached.
 ► The data from this study will serve as a baseline for 
ongoing monitoring and evaluation of the state of the 
research.
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those that are underpowered to detect clinically mean-
ingful effects contribute to research waste.14
In response to the knowledge gaps and priorities iden-
tified by the Consent and Recruitment Standard Develop-
ment Group, we evaluated the consent and recruitment 
procedures for 300 paediatric trials to determine: the 
consent and recruitment strategies used, who trial infor-
mation was targeted to, how incentives were used and 
whether they achieved their recruitment targets.
MethOds
Context
The analyses presented herein are part of a larger study9 15 
in which we characterised the conduct and reporting 
qualities of 300 paediatric trials published in 2012. A full 
description of the study methods appears in a previous 
publication.9
database search
In November 2013, a research librarian searched 
the Cochrane Central Register of Controlled Trials 
(CENTRAL) for randomised trials published in 2012 
(online supplementary file 1). CENTRAL is a compre-
hensive database of reports of randomised and quasi-ran-
domised trials, taken mainly from MEDLINE and 
Embase.16 The 2012 publication date coincided with the 
publication of the StaR Child Health Standards.
trial selection
A total of 2296 unique records were identified via the 
search. We ordered these randomly in Excel (V.2016; 
Microsoft, Redmond, Washington, USA) and selected the 
first 300 published trials that: (a) recruited participants 
aged 0–18 years or (b) recruited both children and adults 
with an upper age limit of 21 years. The inclusion criteria 
were selected to match those used by Cochrane Child 
Health to select trials for their trials register (which orig-
inate from CENTRAL).17 The sample size coincides with 
our previous evaluation of paediatric trials published in 
2007.15 The sample was not restricted by language, condi-
tion, intervention or outcome type.
data extraction
For each included trial, we extracted data into Research 
Electronic Data Capture18 pertaining to the character-
istics of the: publication, trial design, intervention, trial 
conduct, trial sample, data monitoring committee and 
follow-up, outcomes and conclusions, risk of bias and 
trial registration and protocol.9 We also collected addi-
tional data to address the knowledge gaps and priori-
ties outlined by the Standard Development Groups. An 
author (AG or MPD) verified the extracted data to iden-
tify errors or omissions.
The data extraction guide for the variables included in 
this report is in online supplementary file 2. The primary 
diagnostic category was classified according to the 
WHO’s International Statistical Classification of Diseases 
and Related Health Problems 10th Revision.19 Partic-
ipants’ recruitment location was classified according 
to the World Bank income classification for the 2019 
fiscal year.20 The recruitment strategy was classified as 
standard if the participants provided consent and were 
then randomised in a typical manner (eg, 1:1, 1:2). The 
reasons for recruitment delays were classified based on 
the definitions provided by Kaur et al.21 Incentives were 
categorised as one or more of the following: reimburse-
ments (costs associated with participation that are paid 
back, eg, parking, travel), compensation (participants 
are paid a modest amount for their time and effort), 
tokens of appreciation (a small gift given at the end of 
the trial, usually not known beforehand) and incentive 
payments (typically known before participation and used 
to enhance recruitment). Children were considered to 
be of ‘school age’ if they were >5 years old. Participants 
were considered ‘mature minors’ if they were adoles-
cents or young adults aged ≥12 years. Whether children 
with chronic or comorbid conditions were excluded was 
collected to estimate if children were fairly and equitably 
recruited into the trial.
We referred to protocols, trial registries and asso-
ciated publications to complement data extraction. 
Trial registers were sought via the International Clin-
ical Trials Registry Platform, the International Stan-
dard Randomised Controlled Trials Number (ISRCTN) 
Registry and Google. Trial registers were located for 
46% (n=138/300) of the trials.9 Protocols or companion 
articles were used only when cited in the publications. 
Authors were not contacted to collect consent and 
recruitment details beyond those in published reports.
data analysis
The data were exported to an Excel workbook for 
cleaning and to SPSS Statistics V.23 (IBM, Armonk, New 
York, USA) for descriptive analysis. To determine whether 
the recruitment target was reached, the result of the 
sample size calculation was compared with the number 
of participants enrolled in the trial. The data on the use 
of incentives were stratified by continent because allow-
able incentives for paediatric research vary by region (eg, 
the European Union advocates banning all incentive 
payments for children, while incentive payments for chil-
dren participating in trials are relatively common in the 
USA).10
results
Patient population and consent and recruitment procedures
Most trials recruited from high-income countries20 
(n=202/300, 67%) and 68% (n=205/300) reported 
excluding patients with comorbid or chronic diseases 
(table 1). Only one trial (n=1/300, 0.3%) reported using 
a non-standard recruitment strategy (Zelen’s design, 
whereby participants are randomly allocated to treat-
ment before seeking consent; participants can accept 
or decline the intervention offered). Only one trial 
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(n=1/300, 0.3%) reported a specified amount of time 
(7 days) for participants to decide whether to enrol. 
Seventeen per cent (n=51/300) of trials reported who 
first spoke to the family about participating. The most 
common point of contact was a researcher or clinician 
unknown to the participant (n=28/51, 55%).
Who trial information was targeted to
Most trials reported that consent was obtained 
(n=275/300, 92%), but only 13% (n=39/300) reported 
Table 1 Characteristics of the patient populations and 
recruitment approaches (n=300)
Characteristic n (%)
Recruitment location*
  Low-income country 16 (5.3)
  Lower-middle-income country 33 (11.0)
  Upper-middle-income country 56 (18.7)
  High-income country 202 (67.3)
Exclusion of patients with chronic diseases
  Yes 205 (68.3)
  No 59 (19.7)
  Unclear 36 (12.0)
Recruitment strategy
  Standard 299 (99.7)
  Not standard 1 (0.3)
Time to decide whether to enrol
  Limited 1 (0.3)
  Not reported 299 (99.7)
Who first approached the patient
  Child’s clinician 8 (2.7)
  Researcher or clinician unknown to 
patient
28 (9.3)
  Other 15 (5.0)
  Not reported 249 (83.0)
Consent obtained and reported
  Yes 275 (91.7)
  No 25 (8.3)
Who obtained consent
  Child’s clinician 2 (0.7)
  Researcher or clinician unknown to 
patient
31 (10.3)
  Other 6 (2.0)
  Not reported 261 (87.0)
How consent was provided
  Parental permission 149 (49.7)
  Parental permission and participant 
assent
117 (39.0)
  Consent of a mature minor 4 (1.3)
  Not reported 30 (10.0)
Patients/families involved in trial design/conduct
  Reported 9 (3.0)
  Not reported 291 (97.0)
Source of recruitment†
  Inpatients 74 (24.7)
  Outpatients 51 (17.0)
  Clinician’s office 38 (12.7)
  School 70 (23.3)
  Community 44 (14.7)
Continued
Characteristic n (%)
  Other 14 (4.7)
  Unclear or not reported 56 (18.7)
Primary diagnostic category‡
  Mental and behavioural disorders 50 (16.7)
  Infectious and parasitic disease 39 (13.0)
  Respiratory system 30 (10.0)
  Conditions originating in the perinatal 
period
28 (9.3)
  Endocrine, nutritional and metabolic 
diseases
25 (8.3)
  Oral health 19 (6.3)
  Factors influencing health status and 
contact with health services
13 (4.3)
  Digestive system 10 (3.3)
  Blood, blood forming organs and 
immune mechanism
7 (2.3)
  Congenital malformations, deformations 
and chromosomal abnormalities
7 (2.3)
  Nervous system 7 (2.3)
  Eye and adnexa 5 (1.7)
  Ear and mastoid process 4 (1.3)
  Injury, poisoning and consequences of 
external causes
4 (1.3)
  Circulatory system 3 (1.0)
  External causes of morbidity and 
mortality
3 (1.0)
  Genitourinary system 3 (1.0)
  Musculoskeletal system and connective 
tissue
3 (1.0)
  Neoplasms 3 (1.0)
  Pregnancy, childbirth and the 
puerperium
2 (0.7)
  Skin and subcutaneous tissue 2 (0.7)
  Other 33 (11.0)
*Defined according to the World Bank income classification, 2019 
fiscal year.20 Some trials recruited from more than one category.
†Total exceeds 300 because some trials reported multiple sources.
‡Defined according to the International Statistical Classification 
of Diseases and Related Health Problems 10th Revision (2010).18 
These data have been previously reported, but are shown here for 
context.9
Table 1 Continued 
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who obtained consent. Ninety per cent (n=270/300) 
of trials reported how consent was provided. Among 
these, 55% (n=149/270) obtained consent via parental 
permission and 43% (n=117/270) via parental permis-
sion combined with participant assent. Four trials (2%) 
reported only obtaining the consent of a mature minor. 
These included trials of the following: corrective exer-
cises for scoliosis, prevention of acute knee injuries in 
athletes, bright-light therapy for non-seasonal depression 
and oxidant and antioxidant levels in patients with ortho-
dontic tooth movement. Of trials that included school-
aged participants (>5 years old; n=196/300, 65%), 68% 
(n=117/172) reported obtaining participant assent and 
32% (n=55/172) reported obtaining parental permission 
only. Three per cent (n=9/300) of trials reported that 
participants and families were involved in the design or 
conduct of the trial.
Nineteen per cent (n=56/300) of trials did not report 
the recruitment setting (or it was unclear). When clearly 
reported, most often trials recruited participants from 
inpatient populations (n=74/300, 25%), outpatient 
populations (n=51/300, 17%) or schools (n=70/300, 
23%).
About two-thirds (n=184/300, 61%) of trials reported 
how families were informed about the opportunity 
to participate (table 2). Of these, 59% (n=108/184) 
reported that parents were approached during a health-
care visit, 8% (n=15/184) used mail invites, 4% (n=7/184) 
approached parents by telephone, 14% (n=26/184) 
used media messages (eg, via the radio, newspaper or a 
website) and 11% (n=20/184) used pamphlets. Other 
methods (n=63/184, 34%) included schools (ie, school 
staff contacted parents about the trial), community 
contacts and word of mouth; and identifying potential 
participants through chart reviews or previous trials. 
Sixteen per cent (n=30/184) of trials used multiple 
means of informing families about the opportunity to 
participate.
Half (n=151/300, 50%) of the trials reported the 
person who was the target of the trial information. Of 
these, 58% (n=88/151) targeted the information towards 
parents only, 5% (n=7/151) towards mature minors only 
and 37% (n=56/151) towards parents and children. 
Although it was not reported, we assumed that an addi-
tional 13% (n=40/300) intended the information to 
be for parents, as participants were infants or children 
less than school age. When it was reported, all trials that 
included only participants ≤5 years of age directed the 
information to parents only (n=64/64, 100%). Most trials 
(n=65/87, 75%) that included participants >5 years of 
age directed trial information either to mature minors 
only or both parents and children.
use of incentives
Most trials did not report whether incentives were used 
(n=253/300, 84%) and five (2%) reported not using 
incentives. Fourteen per cent (n=42/300) of trials 
reported using incentives. These were most often in 
the form of compensation (n=21/42, 50%) and tokens 
of appreciation (n=12/42, 29%) (five studies (12%) 
provided reimbursements and seven (17%) provided 
incentive payments). Reported compensation amounts 
varied, for example, free dental care and $20 for fami-
lies participating in a 5-year dental amalgam trial; $5–$10 
gift cards for adolescents participating in a trial of tele-
phone-based preventive health education and counsel-
ling. Tokens of appreciation also varied, for example, an 
insecticide impregnated bed net and soap for families 
participating in a trial of therapeutic food for catch-up 
growth after malaria; $40 for teachers participating in 
a trial of a school-based intervention. Tables 3 and 4 
show the reported incentive use and types of incentives 
used stratified by continent of recruitment. The use 
Table 2 Formats used to present trial information to 
participants and families (n=300)
Characteristic n (%)
How the family heard about the trial*
  Approached during healthcare visit 108 (36.0)
  Mailing 15 (5.0)
  Generalised mailing 4 (1.3)
  Targeted mailing 9 (3.0)
  Personalised mailing 2 (0.7)
  Phone calls 7 (2.3)
  Media 26 (8.7)
  Pamphlets 20 (6.7)
  Other 63 (21.0)
  Not reported 116 (38.7)
Who trial information was targeted to
  Parents 88 (29.3)
  Mature minors 7 (2.3)
  Parents and children 56 (18.7)
  Not reported 149 (49.7)
*Some trials used multiple approaches.
Table 3 Use of incentives stratified by recruitment 
continent (n=300)*
Recruitment 
continent N
Use of incentives, n (%)
Yes No
Not 
reported
Africa 26 3 (11.5) 1 (3.8) 22 (84.6)
Asia 82 1 (1.2) 2 (2.4) 79 (96.3)
Australia 18 3 (16.7) 0 (0.0) 15 (83.3)
Europe 54 2 (3.7) 3 (5.6) 49 (90.7)
North America 119 33 (27.7) 0 (0.0) 86 (72.3)
South America 9 0 (0.0) 0 (0.0) 9 (100.0)
*Some studies recruited participants from more than one 
continent.
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of incentives was most often reported in studies that 
recruited from North America (n=33/119, 28%). All 
studies that offered incentive payments recruited from 
North America.
The child was often the recipient of the incentive, rather 
than the parents or family: 20% (n=1/5) of reimburse-
ments (eg, $5 for a bus ticket for travel), 48% (n=10/21) 
of compensation incentives (eg, $10 for completing a 
survey), 50% (n=6/12) of tokens of appreciation (eg, $10 
gift certificate), and 83% (n=5/6) of incentive payments 
(eg, $50 supermarket gift cards) were intended for the 
participant.
recruitment target attainment
About half (n=145/300, 48%) of the trials reported suffi-
cient information to determine if the recruitment target 
was achieved (table 5). Of these, 70% (n=102/145) 
recruited their target sample size. Of the studies that 
recruited their target sample size, four (3.9%) reported 
using incentives and three (2.9%) explicitly reported not 
using incentives.
Recruitment delays were reported in 6% (n=19/300) of 
trials and were most often due to patient-level (n=10/19, 
53%; eg, travel, duration of trial, preferences) or trial-
level factors (n=9/19, 47%; eg, funding, trial manage-
ment, feasibility). Strategies to address recruitment delays 
included stopping the trial before the recruitment target 
was achieved (n=13/19, 68%), extending the recruit-
ment period (n=3/19, 16%), adding trial sites (n=2/19, 
11%), modifying the eligibility criteria (n=3/19, 16%) 
and modifying the incentives (n=1/19, 5%).
dIsCussIOn
This study addresses some of the knowledge gaps and 
priorities identified by StaR Child Health’s Consent and 
Recruitment Standard Development Group.3 We found 
that details of consent and recruitment procedures were 
infrequently reported within publications of paediatric 
trials. Although most trials reported obtaining consent, 
elaboration on the consent and recruitment process was 
not common. Our previous evaluation of risk of bias and 
trial registration among the same sample of trials and 
comparison with trials published in 2007 showed that 
some aspects of trial reporting had improved over time 
(eg, reporting of allocation concealment improved and 
trial registration doubled). Because the trials evaluated 
herein were undertaken before the publication of the 
StaR Child Health Standards (and prior to the develop-
ment of a number of international paediatric trials initi-
atives to improve infrastructure and research capacity in 
child health),10 it is reasonable to speculate that research 
published today would be more completely reported 
compared with what we have presented. Nevertheless, 
Table 4 Types of incentives used stratified by continent (n=42)*
Recruitment continent N
Types of incentives used, n (%)
Compensation Tokens of appreciation Reimbursements Payments
Africa 3 2 (66.7) 1 (33.3) 1 (33.3) 0 (0.0)
Asia 1 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0)
Australia 3 1 (33.3) 0 (0.0) 2 (66.7) 0 (0.0)
Europe 2 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
North America 33 16 (48.5) 10 (30.3) 2 (6.1) 7 (21.2)
South America 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
*Some studies offered multiple types of incentives.
Table 5 Recruitment target attainment (n=300)
Characteristic n (%)
Sample size
  Calculation reported 155 (51.7)
  Recruitment target reached* 102/145 (70.3)
Recruitment delays reported
  Yes 19 (6.3)
  No 281 (93.7)
Types of recruitment delays†
  Patient-level factors 10/19 (52.6)
  Trial-level factors 9/19 (47.4)
  Site-level factors 1/19 (5.3)
  Trial-team-level factors 1/19 (5.3)
  Not specified 4/19 (21.1)
How recruitment delays were addressed‡
  Stopping the trial before reaching the 
target
13/19 (68.4)
  Extending the recruitment period 3/19 (15.8)
  Modifying the eligibility criteria 3/19 (15.8)
  Adding additional trial sites 2/19 (10.5)
  Modifying incentives 1/19 (5.3)
*Based on sample size calculation and number randomised; data 
for this calculation were unavailable for 10 trials that reported a 
sample size calculation.
†Total exceeds 19 because some trials reported more than one 
type of delay.
‡Total exceeds 19 because some trials reported more than one 
method.
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reporting shortcomings likely remain and ongoing evalu-
ation of the state of the research will be needed to inform 
areas in particular need for improvement.
Despite being widely accepted as a requirement,11 22 
there remains ambiguity about what constitutes assent 
in paediatric trials,23 which children are capable of 
providing it23 and how it should be reported.24 Recently, 
Tait and Geisser established an operational definition of 
assent, including recommendations about the level of 
information appropriate for different ages.25 Neverthe-
less, guidance on the age at which children must provide 
assent varies substantially by country.26–28 It also remains 
unclear whether the level of detail regarding consent 
and recruitment procedures required by research ethics 
boards is appropriate or necessary in published reports 
of paediatric trials. In 2010, Saint-Raymond et al called 
attention to the need for reporting guidelines specific to 
research with children.24 The development of paediatric 
adaptations of the Standard Protocol Items: Recommen-
dations for Interventional Trials29 and Consolidated Stan-
dards of Reporting Trials30 statements is under way.31
Fewer than 20% of trials reported who approached 
families to participate. Although a relationship to the 
person obtaining consent can encourage recruitment,32 
when the person is the child’s healthcare provider 
parents may worry that refusing participation will impact 
their child’s quality of care.23 In most trials of school-
aged children, trial information was directed to both 
parents and children. Parents and children’s under-
standing of trial materials are fundamental to ethical and 
efficient recruitment.3 Not understanding trial informa-
tion discourages parents and children from enrolling in 
trials,32 and some presentations of the benefits and risks 
of trial participation (eg, as dense text documents) can 
be difficult for parents to understand.33 The integrated 
consent model in which clinicians engage the trial partic-
ipant in a consent conversation similar to usual care 
and additionally present the opportunity for the rando-
misation of previously validated treatment options has 
been proposed.34 This approach has been suggested for 
low-risk and pragmatic trials,34 however the applicability 
to paediatric trials needs to be established.
Few trials reported whether incentives were used, but 
of those that did, many were intended for children. 
Trial participation can be costly for families, and there 
is general consensus that they should be reimbursed for 
the related expenses (eg, travel, parking) at a rate that 
is sufficient but does not lead them to undervalue risks 
or coerce them to consent.22 32 As children value incen-
tives differently than adults, their provision to minors is 
controversial.3 10 When incentives are used, it is critical 
that children understand the implications of the trial 
and that the incentives do not influence their decision 
to participate.3 10 As mentioned previously, allowable 
payment incentives for children who participate in 
trials vary by region. As expected, just 4% of studies that 
recruited in Europe reported providing incentives, all 
of which were in the form of compensation. Conversely, 
28% of studies that recruited in North America reported 
providing incentives, and 21% of these were in the form 
of payments. Given the poor reporting of incentive use, it 
was not possible to conclude whether offering incentives 
improved the chance of attaining the recruitment target. 
Nevertheless, from the few studies that reported whether 
or not incentives were used, it did not appear that this 
was the case.
Seventy per cent of trials met their recruitment targets. 
This is substantially greater than the 29% reported 
in St-Louis et al’s review of paediatric general surgical 
trials,35 and the 55% in Sully et al’s review of multicentre 
trials in the UK.36 Failing to meet the recruitment target 
contributes to research waste when the trial is underpow-
ered to detect clinically important differences.37 Due to 
reporting deficiencies, we could only ascertain whether 
trials achieved their recruitment targets for half of the 
sample. Whether transparent reporting is biased towards 
trials that meet their recruitment targets is not yet known.
strengths and limitations
We have highlighted a number of conduct and/or 
reporting gaps in an effort to contribute to the ongoing 
research agenda. Our sample will serve as a baseline for 
ongoing monitoring of consent and recruitment proce-
dures in paediatric trials. The extracted data were limited 
to those available within published reports, therefore we 
cannot ascertain the extent to which the findings reflect 
conduct and/or reporting shortcomings. Because the 
sample included studies that reported on participants 
aged 0–21 years and from countries that varied by income, 
the sample was highly heterogeneous (ie, consent proce-
dures are different for infants compared with adolescents 
and young adults, and are highly influenced by cultural 
norms and local ethical standards) limiting generalisa-
bility to specific age groups or regions by income level. 
Further investigation into trials examining participants 
in more discrete age groups (eg, infants, young children, 
adolescents) and in regions of a specific income level (eg, 
low income, middle income) would be of interest. As we 
used a sample of trials published in 2012, the findings 
may not be generalisable to other years.
COnClusIOns
In our sample, five reporting shortcomings were evident: 
how families were recruited, who obtained consent and/
or assent and how, who trial information was directed 
to, whether incentives were used and sufficient data 
to determine if the recruitment target was met. Forth-
coming reporting guidance specific to paediatric trials,31 
and the StaR Child Health Standards3 may contribute 
to improving the conduct and reporting of paediatric 
trials in this priority area. Using this study as a baseline, 
continued monitoring of the state of the research will 
allow for the identification of changes over time and the 
need for the translation of evidence-based standards into 
forms that are appealing and accessible to trialists.
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